De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Maravai LifeSciences Holdings Toekomstige groei
Future criteriumcontroles 1/6
Maravai LifeSciences Holdings zal naar verwachting groeien in winst en omzet met respectievelijk 89.7% en 10.2% per jaar. De winst per aandeel zal naar verwachting groeien met 102.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -0.8% zijn.
Belangrijke informatie
89.7%
Groei van de winst
102.9%
Groei van de winst per aandeel
| Life Sciences winstgroei | 17.6% |
| Inkomstengroei | 10.2% |
| Toekomstig rendement op eigen vermogen | -0.8% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 12 Sep 2024 |
Recente toekomstige groei-updates
Recent updates
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) 29% Jump Shows Its Popularity With Investors
Jul 18
Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?
Jul 15Maravai: Embedded Expectations Remain Too High Considering Economic Calculus
Jul 12RGA Investment Advisors - Maravai: Two Elite Assets With Other-Worldly Margins Wrapped In One
Jun 12Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%
May 14An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued
Apr 07Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Feb 28Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price
Dec 19Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates
Aug 14Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?
Feb 28Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 01Maravai Lifesciences temporarily reinstates Carl Hull as CEO
Oct 19Maravai LifeSciences appoints former Danaher executive as CEO
Oct 03Maravai LifeSciences Holdings GAAP EPS of $0.53 beats by $0.15, revenue of $242.73M beats by $9.51M
Aug 04Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
Jun 27Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 25% Below Its Share Price
Mar 29Maravai Faces Skeptical Investors As Pandemic Enters New Period
Jan 27Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price Could Signal Some Risk
Dec 02Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 344 | -18 | 10 | 40 | 10 |
| 12/31/2025 | 297 | -22 | 13 | 43 | 14 |
| 12/31/2024 | 275 | -28 | -15 | 15 | 14 |
| 6/30/2024 | 279 | -132 | -17 | 31 | N/A |
| 3/31/2024 | 274 | -131 | -31 | 33 | N/A |
| 12/31/2023 | 289 | -119 | 61 | 126 | N/A |
| 9/30/2023 | 420 | 25 | 163 | 218 | N/A |
| 6/30/2023 | 544 | 75 | 268 | 314 | N/A |
| 3/31/2023 | 718 | 153 | 437 | 459 | N/A |
| 12/31/2022 | 883 | 220 | 519 | 536 | N/A |
| 9/30/2022 | 907 | 238 | 479 | 495 | N/A |
| 6/30/2022 | 920 | 248 | 479 | 491 | N/A |
| 3/31/2022 | 895 | 226 | 478 | 493 | N/A |
| 12/31/2021 | 799 | 182 | 354 | 369 | N/A |
| 9/30/2021 | 669 | 150 | 371 | 389 | N/A |
| 6/30/2021 | 552 | 127 | 308 | 335 | N/A |
| 3/31/2021 | 381 | 78 | 155 | 181 | N/A |
| 12/31/2020 | 284 | 77 | 127 | 152 | N/A |
| 12/31/2019 | 143 | -8 | 7 | 24 | N/A |
| 12/31/2018 | 124 | -18 | -4 | 0 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat MRVI de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat MRVI de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat MRVI de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van MRVI ( 10.2% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).
Hoge groei-inkomsten: De omzet van MRVI ( 10.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat MRVI binnen 3 jaar verliesgevend zal zijn.